Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Genk – page 112

1 420 clinical trials in Genk, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Genk at a glance
1 420
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 420 trials in Genk

Open in trial search

Colitis ulcerative+2

Not recruiting

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Acute coronary syndrome

Not recruiting

Study on Reducing Bleeding by Omitting Aspirin in Patients with Non-ST Elevation Acute Coronary Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Amsterdam UMC Stichting

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Embolism

Not recruiting

Study on REGN9933 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer stage III

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Dyspepsia

Not recruiting

Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aluminium Oxide
  • Sponsor:UZ Leuven

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Multiple sclerosis+4

Not recruiting

Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Antwerp University Hospital

High-grade B-cell lymphoma

Not recruiting

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Fallopian tube cancer+1

Not recruiting

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Genk

What the registry says about research in the country

01 Respiratory Disease Trials

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention in older adults. Studies evaluate innovative vaccine combinations and immune responses in participants over 60 years.

  • RSV and human metapneumovirus vaccines
  • High-dose Influenza vaccines
  • Vaccine co-administration studies

Multiple trials aim to enhance protection against respiratory infections in vulnerable populations.

02 Cardiovascular Research

Comprehensive studies addressing various aspects of heart disease and related conditions, including innovative treatments for hypertrophic cardiomyopathy and heart failure.

  • Acute Heart Failure treatments
  • Pulmonary Hypertension therapies
  • Cardiovascular disease prevention

Trials explore new therapeutic approaches for managing complex cardiac conditions.

03 Autoimmune Conditions

Clinical research examining treatments for various autoimmune disorders, including innovative therapies for rheumatoid arthritis and Sjögren's syndrome.

  • Psoriatic Arthritis treatments
  • Rheumatoid Arthritis therapies
  • Primary Sjögren's Disease interventions

Studies focus on improving treatment outcomes and quality of life for patients with autoimmune conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.